Bioqual, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOQ research report →
Price Chart
About the company
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue.
- CEO
- Hanne Andersen-Elyard
- IPO
- 2002
- Employees
- 278
- HQ
- Rockville, MD, US
Get TickerSpark's AI analysis on BIOQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $29.52M
- P/E
- -7.08
- PEG
- -0.01
- P/S
- 0.74
- P/B
- 0.91
- EV/EBITDA
- -57.32
- Div Yield
- 0.00%
- Gross Margin
- 3.59%
- Op Margin
- -11.19%
- Net Margin
- -10.44%
- ROE
- -11.99%
- ROIC
- -6.85%
Latest fiscal year · YoY change
- Revenue
- $39.95M-18.3%
- Gross Profit
- $1.43M+175.6%
- Op Income
- $-4,471,128
- Net Income
- $-4,168,571-297.7%
- EPS
- $-4.66-298.3%
- OCF Growth
- -88.1%
- FCF Growth
- -102.5%
- 52W High
- $40.00
- 52W Low
- $32.50
- 50D MA
- $32.80
- 200D MA
- $35.26
- Beta
- -0.09
- RSI (14)
- 93
- Avg Volume
- 18
No earnings-call transcripts are available for BIOQ yet.
- Free Float
- 99.6%
- Shares Outstanding
- 894.42K
- Float Shares
- 890.75K
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 11 | WILLIAMS FRANK E JR | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIOQ coverage
Recent articles, reports, and earnings notes.
No research on BIOQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOQ report →CORRECTING and REPLACING BIOQUAL Presents Financial Results for Fiscal Year 2026
businesswire.com · Sep 30
BIOQUAL Presents Financial Results for Fiscal Year 2026
businesswire.com · Sep 22
BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2026
businesswire.com · Apr 21
Reviewing Bioqual (OTCMKTS:BIOQ) and Option Care Health (NASDAQ:OPCH)
defenseworld.net · Feb 7
BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026
businesswire.com · Jan 22
Financial Analysis: Encompass Health (NYSE:EHC) vs. Bioqual (OTCMKTS:BIOQ)
defenseworld.net · Oct 26
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2026
businesswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.